Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | APMD | DNA |
|---|---|---|
| Price | $18.04 | $11.47 |
| Change today | ▼ 3.27% | ▼ 7.57% |
| Market cap | $751.02M | $772.39M |
| Return, 3 months | – | +17.9% |
| Return, year to date | – | +38.0% |
| Return, 1 year | – | -28.7% |
| P/E (TTM) | 4.6 | -2.3 |
| P/B | -4.3 | 1.8 |
| P/E percentile vs own 5y | 33rd | 30th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -29.4% | -48.5% |
| Net profit growth (YoY) | +281.3% | +22.5% |
| Gross margin | 93.9% | 68.0% |
| Operating margin | 30.9% | -228.6% |
| Net margin | 252.6% | -219.6% |
| Return on equity | – | -56.3% |
| Analyst target vs. price | +179.0% | -39.0% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 33 | 57 |
| 30-day volatility | 96.1% | 125.7% |
| Max drawdown, 1 year | -44.6% | -66.0% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
